



Table of Contents

List of Tables	VI
List of Figures	X

Chapter	Title	Page
Chapter 1:	Introduction	1
Chapter 2:	Literature review	
2.1	Skin Barrier	13
2.2	Topical Drug Delivery	15
2.2.1	Routes of Penetration	16
2.2.2	Penetration Enhancement through Optimisation of Drug and Vehicle Properties	20
2.2.3	Penetration Enhancement by Stratum Corneum Modification	21
2.2.4	Determination of Percutaneous Absorption	22
2.3	Microemulsions	26
2.3.1	Theories of Microemulsion Formulation	28
2.3.2	Factors Affecting the Type of Microemulsion and Phase Behaviour of the Microemulsion	31
2.3.3	Formation of Microemulsion and Phase Behavior	34
2.3.4	Characterization of Microemulsions	38
2.3.5	Microemulsions for Dermal Delivery	41
2.4	Atopic Dermatitis	44
2.4.1	Pathophysiology	46
2.4.2	Multifunctional Role for IgE in Atopic Skin Inflammation	50
2.4.3	Role of the Epidermis in Barrier Function	51
2.4.4	Immunological Triggers	51
2.4.5	Animal models of Atopic Dermatitis	52
2.4.6	Management of Atopic Dermatitis	57
2.4.7	Pharmacologic Treatments	59
2.4.7.1	Topical Corticosteroids	59
2.4.7.2	Topical Calcineurin Inhibitors	67
2.4.7.3	Coal Tar Preparations	70
2.4.7.4	PDE Inhibition	70
2.4.7.5	Systemic Therapies	71
2.4.7.6	Supportive Treatments	74

2.4.7.7	Developing a treatment algorithm with combinational, rotational and sequential treatment	76
2.5	Drug Profiles	81
2.5.1	Halobetasol Propionate	81
2.5.2	Tacrolimus	84
2.6	References	88
 Chapter 3: Analytics		
3.1	Introduction	103
3.2	Materials and Instruments	103
3.3	Methods	104
3.3.1	Method Validation Parameters for UV Spectroscopic Method	104
3.3.2	Method Validation Parameters for HPLC Method	105
3.3.3	Direct Estimation of Halobetasol Propionate by UV Spectrometry	105
3.3.4	Colorimetric Estimation of Corticosteroid by Tetrazolium blue method	106
3.3.5	Estimation of Halobetasol propionate and Tacrolimus by HPLC	107
3.3.6	Measurement of IgE in Biological Samples of Mice by ELISA	110
3.4	Results	112
3.4.1	Estimation of Halobetasol Propionate by UV Spectroscopic Method	112
3.4.2	Colorimetric Estimation of Corticosteroid by Tetrazolium blue Method	114
3.4.3	Estimation of Halobetasol Propionate by HPLC Method	117
3.4.4	Estimation of Tacrolimus by HPLC Method	119
3.4.5	Estimation of Tacrolimus by HPLC Method (Methanol: water)	119
3.4.5	Estimation of Tacrolimus by HPLC Method (Acetonitrile : water)	121
3.4.6	Measurement of IgE in Biological Samples of Mice by ELISA	123
3.5	Discussion	124
3.6	References	127
 Chapter 4: Formulation & Characterization		
4.1	Introduction	129
4.2	Materials and Instruments	130
4.3	Methods	130
4.3.1	Solubility Determination	130
4.3.2	Preparation of Microemulsion	131
4.3.3	Optimization of ME preparation	132
4.3.4	Preparation of Cetomacrogol Cream Base and incorporation	133

	of microemulsion	
4.3.5	Characterization	134
4.3.6	Stability Studies	136
	4.3.6.1 Long term stability study	136
	4.3.6.2 Accelerated stability study	137
4.4	Results	138
4.4.1	Solubility Studies	138
4.4.2	Preparation Optimization and Characterization of Halobetasol Propionate Microemulsion	140
4.4.3	Preparation Optimization and Characterization of Tacrolimus Microemulsion	152
4.4.4	Transmission Electron Microscopy	164
4.4.5	Stability Studies	167
4.5	Discussion	171
4.5.1	Halobetasol propionate microemulsion and microemulsion based cream	171
4.5.2	Tacrolimus microemulsion and microemulsion based cream	175
4.6	References	179
 Chapter 5: <i>In-Vitro</i> & <i>Ex -Vivo</i> Studies		
5.1	Introduction	181
5.2	Methods	187
	5.2.1 Drug diffusion studies across artificial membrane	187
	5.2.2 Drug permeation and skin retention studies in rodent and human cadaver skin	188
5.3	Results	191
	5.3.1 Halobetasol Propionate	191
	5.3.2 Tacrolimus	194
5.4	Discussion	196
5.5	References	201
 Chapter 6: Irritation & Toxicity Studies		
6.1	Introduction	203
6.2	Methods	207
	6.2.1 Sub-Acute dermal toxicity testing	207
	6.2.2 MTT assay	208
	6.2.3 Evaluation of Skin Irritancy in Human Subjects	209
6.3	Results	212
	6.3.1 Sub-Acute Dermal Toxicity Study	212
	6.3.2 MTT Assay	218
	6.3.3 Human Acceptance Testing	219
6.4	Discussion	220
6.5	References	222

Chapter 7: <i>In-Vivo</i> Pharmacodynamic Studies in Murine Model	
7.1 Introduction	225
7.2 Methods	227
7.2.1 Fluorescent Microscopy	227
7.2.2 Elicitation and Sensitization Protocol	227
7.2.3 Treatment Protocol	227
7.2.4 Dermatitis Score	228
7.2.5 Ear Swelling Studies	228
7.2.6 Measurement of Serum IgE	228
7.2.7 Histopathology	229
7.2.8 Cytokine Gene Expression by RT-PCR analysis	229
7.3 Results	233
7.3.1 Halobetasol Propionate	233
7.3.2 Tacrolimus	246
7.4 Discussion	256
7.4.1 Halobetasol Propionate	256
7.4.2 Tacrolimus	262
7.5 References	268
 Chapter 8: Clinical Studies	
8.1 Introduction	271
8.2 Methods	276
8.2.1 Skin Blanching Assay	276
8.2.2 Protocol for comparative skin blanching bioassay of halobetasol propionate formulations.	276
8.2.3 Pilot Study in Dermatitis Patients	280
8.2.4 Protocol for comparative evaluation of halobetasol formulations in treatment of steroid responsive dermatoses.	281
8.3 Results	286
8.3.1 Skin Blanching Bioassay	286
8.3.2 Pilot Clinical Studies	289
8.4 Discussion	295
8.5 References	298
 Chapter 9: Development of Combination	
9.1 Introduction	301
9.2 Methods	302
9.2.1 Physical and Chemical Compatibility Testing	302
9.2.3 Preparation and Characterization of Combination Microemulsion Cream	303
9.2.4 Drug Diffusion across Artificial Membrane	303
9.2.5 Ex-vivo Drug diffusion and skin retention study	303
9.2.6 Pharmacodynamic Study in Murine Model	303

9.3	Results	305
9.4	Discussion	320
9.5	References	324
Chapter 10: Summary & Conclusion		325